Analysis of HIV latent infection model with multiple infection stages and different drug classes

References

• K.W. Ahn and M.J. Root, Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors, J. Biol. Chem. 292 (40) (2017), pp. 16498–16510.
   PubMed Web of Science ®Google Scholar
• A. Alshorman, C. Samarasinghe, W. Lu, and L. Rong, An HIV model with age-structured latently infected cells, J. Biol. Dyn. 11 (sup1) (2017), pp. 192–215.
   PubMed Web of Science ®Google Scholar
• A. Alshorman, X. Wang, M.J. Meyer, and L. Rong, Analysis of HIV models with two time delays, J. Biol. Dyn. 11 (sup1) (2017), pp. 40–64.
   PubMed Web of Science ®Google Scholar
• Antiretroviral Therapy Cohort Collaboration, Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, Lancet HIV. 4 (8) (2017), pp. e349–e356.
   Google Scholar
• S. Ávila-Ríos, C. García-Morales, M. Matías-Florentino, K.A. Romero-Mora, and D. Tapia-Trejo, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey, Lancet HIV. 3 (12) (2016), pp. e579–e591.
   PubMed Web of Science ®Google Scholar
• G. Barbaro, A. Scozzafava, A. Mastrolorenzo, and C.T. Supuran, Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome, Curr. Pharm. Des. 11 (14) (2005), pp. 1805–1843.
   PubMed Web of Science ®Google Scholar
• B.R. Bavinton, A.N. Pinto, N. Phanuphak, B. Grinsztejn, and G.P. Prestage, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study, Lancet HIV. 5 (8) (2018), pp. e438–e447.
   PubMed Web of Science ®Google Scholar
• J.N. Blankson, D. Persaud, and R.F. Siliciano, The challenge of viral reservoirs in HIV-1 infection, Annu. Rev. Med. 53 (1) (2002), pp. 557–593.
   PubMedGoogle Scholar
• D. Boden, A. Hurley, L. Zhang, Y. Cao, and Y. Guo, et al. HIV-1 drug resistance in newly infected individuals, JAMA 282 (12) (1999), pp. 1135–41.
   PubMed Web of Science ®Google Scholar
• V. Briz, E. Poveda, and V. Soriano, HIV entry inhibitors: mechanisms of action and resistance pathways, J. Antimicrob. Chemother. 57 (4) (2006), pp. 619–627.
   PubMed Web of Science ®Google Scholar
• X. Cao, F.A. Basir, X. Li, and P.K. Roy, Impact of combined therapy in HIV-1 treatment: A double impulsive approach, Int. J. Appl. Comput. Math. 6 (2020), pp. 106.
   Google Scholar
• A. Castagna, P. Biswas, A. Beretta, and A. Lazzarin, The appealing story of HIV entry inhibitors, CNS Drugs. 65 (7) (2005), pp. 879–904.
   Google Scholar
• N. Chomont, M. El-Far, P. Ancuta, L. Trautmann, and F.A. Procopio, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation, Nat. Med. 15 (8) (2009), pp. 893–900.
   PubMed Web of Science ®Google Scholar
• S. Chowdhury, P.K. Roy, and R.J. Smith, Mathematical modelling of enfuvirtide and protease inhibitors as combination therapy for HIV, Int. J. Nonlinear Sci. Numer. Simul. 17 (6) (2016), pp. 259–275.
   Web of Science ®Google Scholar
• T.W. Chun, L. Carruth, D. Finzi, X. Shen, and J.A. DiGiuseppe, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection, Nature. 387 (6629) (1997), pp. 183–188.
   PubMed Web of Science ®Google Scholar
• M.S. Cohen, Y.Q. Chen, M. McCauley, T. Gamble, and M.C. Hosseinipour, et al. Antiretroviral therapy for the prevention of HIV-1 transmission, N. Engl. J. Med. 375 (9) (2016), pp. 830–839.
   PubMed Web of Science ®Google Scholar
• F. Curreli, Y.D. Kwon, D.S. Belov, R.R. Ramesh, and A.V. Kurkin, et al. Synthesis, antiviral potency, in vitro ADMET, and X-ray structure of potent CD4 mimics as entry inhibitors that target the Phe43 cavity of HIV-1gp120, J. Med. Chem. 60 (7) (2017), pp. 3124–3153.
   PubMed Web of Science ®Google Scholar
• F. Curreli, D.S. Belov, Y.D. Kwon, R. Ramesh, and A.M. Furimsky, et al. Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120, Eur. J. Med. Chem. 154 (2018), pp. 367–391.
   PubMed Web of Science ®Google Scholar
• O. Diekmann, J.A.P. Heesterbeek, and J.A.J. Metz, On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations, J. Math. Biol.28 (4) (1990), pp. 365–382.
   PubMed Web of Science ®Google Scholar
• J.B. Dinoso, S.Y. Kim, A.M. Wiegand, S.E. Palmer, and S.J. Gange, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy, PNAS 106 (23) (2009), pp. 9403–9408.
   PubMed Web of Science ®Google Scholar
• D.A. Donahue, R.D. Sloan, B.D. Kuhl, T. Bar-Magen, and S.M. Schader, et al. Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture, Antimicrob. Agents Chemother.54 (3) (2010), pp. 1047–1054.
   PubMed Web of Science ®Google Scholar
• X. Fengyan, P.A. Edward, L. Liyu, H. Yingchun, and Y. Juan, et al. Current status of the pharmacokinetics and pharmacodynamics of HIV-1 entry inhibitors and HIV therapy, Curr. Drug Metab. 18 (8) (2017), pp. 769–781.
   PubMed Web of Science ®Google Scholar
• D. Finzi, M. Hermankova, T. Pierson, L.M. Carruth, and C. BUCK, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Sciences. 278 (1997), pp. 1295–1300.
   PubMed Web of Science ®Google Scholar
• J.B. Gilmore, A.D. Kelleher, D.A. Cooper, and J.M. Murray, Explaining the determinants of first phase HIV decay dynamics through the effects of stage-dependent drug action, PLoS Comput. Biol. 9 (3) (2013), pp. e1002971.
   PubMed Web of Science ®Google Scholar
• W.C. Greene, The brightening future of HIV therapeutics, Nat. Immunol. 5 (9) (2004), pp. 867–871.
   PubMed Web of Science ®Google Scholar
• R.M. Gulick, New antiretroviral drugs, Clin. Microbiol. Infect. 9 (3) (2003), pp. 186–193.
   PubMed Web of Science ®Google Scholar
• R.M. Gulick, A. Meibohm, D. Havlir, J.J. Eron, and A. Mosley, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine, AIDS. 17 (16) (2003), pp. 2345–2349.
   PubMed Web of Science ®Google Scholar
• T. Guol, Z. Qiu, M. Shen, and L. Rong, Dynamics of a new HIV model with the activation status of infected cells, J. Math. Biol. 82 (6) (2021), pp. 51.
   PubMed Web of Science ®Google Scholar
• S.M. Hammer and L. Pedneault, Antiretroviral resistance testing comes of age, Antivir. Ther. 5 (1) (2000), pp. 23–26.
   PubMed Web of Science ®Google Scholar
• H. Hatano, R. Scherzer, Y. Wu, K. Harvill, and K. Maka, et al. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection, J. Acquir. Immune Defic. Syndr. 61 (3) (2012), pp. 317–325.
   PubMed Web of Science ®Google Scholar
• T.D. Hollingsworth, R.M Anderson, and C. Fraser, HIV-1 transmission, by stage of infection, J. Infect. Dis. 198 (5) (2008), pp. 687–693.
   PubMed Web of Science ®Google Scholar
• J.M. Hyman, J. Li, and E.A. Stanley, The differential infectivity and staged progression models for the transmission of HIV, Math. Biosci. 155 (2) (1999), pp. 77–109.
   PubMed Web of Science ®Google Scholar
• J.M. Hyman and J. Li, The reproductive number for an HIV model with differential infectivity and staged progression, Linear Algebra Its Appl. 398 (2005), pp. 101–116.
   Web of Science ®Google Scholar
• M.O. Ilomuanya, A.T. Hameedat, E.N. Akang, S.O. Ekama, and B.O. Silva, et al. Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis, Future J. Pharm. Sci. 6 (1) (2020), pp. 81.
   PubMed Web of Science ®Google Scholar
• M.C. Jamjian and I.R. McNicholl, Enfuvirtide: first fusion inhibitor for treatment of HIV infection, Am. J. Health Syst. Pharm. 61 (12) (2004), pp. 1242–1247.
   PubMed Web of Science ®Google Scholar
• Jmarchn, HIV-Wikipedia [Internet]. Available at https://en.wikipedia.org/wiki/HIV.
   Google Scholar
• J.M. Kilby and J.J. Eron, Novel therapies based on mechanisms of HIV-1 cell entry, N. Engl. J. Med.348 (22) (2003), pp. 2228–2238.
   PubMed Web of Science ®Google Scholar
• H. Kim and A.S. Perelson, Viral and latent reservoir persistence in HIV-1-Infected patients on therapy, PLoS Comput. Biol. 2 (10) (2006), pp. e135. pp. 1232–1247.
   PubMed Web of Science ®Google Scholar
• M. v. Kleist, S. Menz, and W. Huisinga, Drug-class specific impact of antivirals on the reproductive capacity of HIV, PLoS Comput. Biol. 6 (3) (2010), pp. e1000720.
   PubMed Web of Science ®Google Scholar
• J.P. Lalezari, K. Henry, M. O'Hearn, J.S.G. Montaner, and P.J. Piliero, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for Drug-Resistant HIV infection in north and South America, N. Engl. J. Med. 348 (22) (2003), pp. 2175–2185.
   PubMed Web of Science ®Google Scholar
• A. Lazzarin, B. Clotet, D. Cooper, J. Reynes, and K. Arastéh, et al. Efficacy of enfuvirtide in patients infected with drugresistant HIV-1 in Europe and Australia, N. Engl. J. Med. 348 (22) (2003), pp. 2186–2195.
   PubMed Web of Science ®Google Scholar
• W. Li, L. Lu, W. Li, and S. Jiang, Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015), Expert. Opin. Ther. Pat. 27 (6) (2017), pp. 707–719.
   PubMed Web of Science ®Google Scholar
• H. Liu and J. Zhang, Dynamics of two time delays differential equation model to HIV latent infection, Phys. A. Stat. Mech. Appl. 514 (2019), pp. 384–395.
   Google Scholar
• J. Llibre, M. Buzon, M. Massanella, A. Esteve, and V. Dahl, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study, Antivir. Ther. 17 (2) (2012), pp. 355–364.
   PubMed Web of Science ®Google Scholar
• A.L. Lloyd, The dependence of viral parameter estimates on the assumed viral life cycle: limitations of studies of viral load data, Proc. Biol. Sci. 268 (1469) (2001), pp. 847–854.
   PubMed Web of Science ®Google Scholar
• J. Lou and R. J.Smith, Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide, J. Theor. Biol. 268 (1) (2011), pp. 1–13.
   PubMed Web of Science ®Google Scholar
• L. Lu, P. Tong, X. Yu, C. Pan, and P. Zou, et al. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain, Biochim. Biophys. Acta. 1818 (12) (2012), pp. 2950–2957.
   PubMed Web of Science ®Google Scholar
• G. Magombedze, W. Garira, and E. Mwenje, Modelling the immunopathogenesis of HIV-1 infection and the effect of multidrug therapy: the role of fusion inhibitors in HAART, Math. Biosci. Eng. 5 (3) (2008), pp. 485–504.
   PubMed Web of Science ®Google Scholar
• M.H. Markowitz, B.Y. Nguyen, E. Gotuzzo, F.A. Mendo, and W. Ratanasuwan, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection, J. Acquir. Immune Defic. Syndr. 46 (2) (2007), pp. 125–133.
   PubMed Web of Science ®Google Scholar
• K. Marks and R.M. Gulick, New antiretroviral agents for the treatment of HIV infection, Curr. Infect. Dis. Rep. 6 (4) (2004), pp. 333–339.
   PubMedGoogle Scholar
• D. McMahon, J. Jones, A. Wiegand, S.J. Gange, and M. Kearney, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy, Clin. Infect. Dis. 50(6) (2000), pp. 912–919.
   Google Scholar
• G.B. Melikyan, How entry inhibitors synergize to fight HIV, J. Biol. Chem. 292 (40) (2017), pp. 16511–16512.
   PubMed Web of Science ®Google Scholar
• M.U. Mirza, A. Saadabadi, M. Vanmeert, O.M.H. Salo-Ahen, and I. Abdullah, et al. Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach, Eur. J. Pharm. Sci. 162 (2021), pp. 105827.
   PubMed Web of Science ®Google Scholar
• T. Mizuguchi, S. Harada, T. Miura, N. Ohashi, and T. Narumi, et al. A minimally cytotoxic CD4 mimic as an HIV entry inhibitor, Bioorg. Med. Chem. Lett. 26 (2) (2016), pp. 397–400.
   PubMed Web of Science ®Google Scholar
• J.P. Moore and R.W. Doms, The entry of entry inhibitors: a fusion of science and medicine, Proc. Natl. Acad. Sci. USA. 100 (19) (2003), pp. 10598–10602.
   PubMed Web of Science ®Google Scholar
• J.M. Murray, S. Emery, A.D. Kelleher, M. Law, and J. Chen, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase, AIDS. 21 (17) (2007), pp. 2315–2321.
   PubMed Web of Science ®Google Scholar
• J.M. Murray, A.D. Kelleher, and D.A. Cooper, Timing of the components of the HIV life cycle in productively infected CD 4+ T cells in a population of HIV-Infected individuals, J. Virol. 85 (20) (2011), pp. 10798–10805.
   PubMed Web of Science ®Google Scholar
• G.P. Pattnaik and H. Chakraborty, Entry Inhibitors: Efficient means to block viral infection, J. Membr. Biol. 253 (5) (2020), pp. 425–444.
   PubMed Web of Science ®Google Scholar
• K.A. Pawelek, S. Liu, F. Pahlevani, and L. Rong, A model of HIV-1 infection with two time delays: Mathematical analysis and comparison with patient data, Math. Biosci. 235 (1) (2012), pp. 98–109.
   PubMed Web of Science ®Google Scholar
• A.S. Perelson and P.W. Nelson, Mathematical analysis of HIV-1 dynamics in vivo, SIAM Rev. 41 (1) (1999), pp. 3–44.
   Web of Science ®Google Scholar
• A.S. Perelson, D.E. Kirschner, and R.D. Boer, Dynamics of HIV infection of CD 4+ T cells, Math. Biosci.114 (1) (1993), pp. 81–125.
   PubMed Web of Science ®Google Scholar
• H.H. Pharm and P.R. Skolnik, Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection, Am. Coll. Clin. Pharm. 24(2) (2012), pp. 198–211.
   Google Scholar
• J. Pu, Q. Wang, W. Xu, L. Lu, and S. Jiang, Development of protein-and peptide-based HIV entry inhibitors targeting gp120 or gp41, Viruses 11 (8) (2019), pp. 705.
   PubMed Web of Science ®Google Scholar
• K. Qian, S.L. Morris-Natschke, and K. Lee, HIV entry inhibitors and their potential in HIV therapy, Med. Res. Rev. 29 (2) (2009), pp. 369–393.
   PubMed Web of Science ®Google Scholar
• T.M. Rad, L. Saghaie, and A. Fassihi, HIV-1 entry inhibitors: A review of experimental and computational studies, Chem. Biodivers. 15 (10) (2018), pp. e1800159.
   PubMed Web of Science ®Google Scholar
• B. Ramratnam, S. Bonhoeffer, J. Binley, A. Hurley, and L. Zhang, et al. Rapid production and clearance of HIV-1 andhepatitis C virus assessed by large volume plasma apheresis, Lancet. 354 (9192) (1999), pp. 1782–1785.
   PubMed Web of Science ®Google Scholar
• B. Ramratnam, J.E. Mittler, L. Zhang, D. Boden, and A. Hurley, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy, Nat. Med. 6 (1) (2000), pp. 82–85.
   PubMed Web of Science ®Google Scholar
• W.C. Roda, S. Liu, C. Power, and M.Y. Li, Modeling the effects of latency reversing drugs during HIV-1 and SIV brain infection with implications for the shock and kill strategy, Bull. Math. Biol. 83 (4) (2021), pp. 39.
   PubMed Web of Science ®Google Scholar
• A.J. Rodger, V. Cambiano, T. Bruun, P. Vernazza, and S. Collins, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-Positive partner is using suppressive antiretroviral therapy, JAMA. 316 (2) (2016), pp. 171–181.
   PubMed Web of Science ®Google Scholar
• A.J. Rodger, V. Cambiano, T. Bruun, P. Vernazza, and S. Collins, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study, Lancet. 393 (10189) (2019), pp. 2428–2438.
   PubMed Web of Science ®Google Scholar
• L. Rong and A.S. Perelson, Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy, PLoS Comput. Biol. 5 (10) (2009a), pp. e1000533. pp. 1–18.
   PubMed Web of Science ®Google Scholar
• L. Rong and A.S. Perelson, Modeling HIV persistence, the latent reservoir, and viral blips, J. Theor. Biol. 260 (2) (2009b), pp. 308–331.
   PubMed Web of Science ®Google Scholar
• L. Rong and A.S. Perelson, Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy, PLoS Comput. Biol. 5 (10) (2009c), pp. e1000533.
   PubMed Web of Science ®Google Scholar
• L. Rong and A.S. Perelson, Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips, Math. Biosci. 217 (1) (2009d), pp. 77–87.
   PubMed Web of Science ®Google Scholar
• L. Rong, Z. Feng, and A.S. Perelson, Emergence of HIV-1 drug resistance during antiretroviral treatment, Bull. Math. Biol. 69 (6) (2007), pp. 2027–2060.
   PubMed Web of Science ®Google Scholar
• A.R. Sedaghat, J.B. Dinoso, L. Shen, C.O. Wilke, and R.F. Siliciano, Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle, Proc. Natl. Acad. Sci. USA. 105 (12) (2008), pp. 4832–4837.
   PubMed Web of Science ®Google Scholar
• A.R. Sedaghat, R.F. Siliciano, and C.O. Wilke, Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir, Antivir. Ther. 14 (2) (2009), pp. 263–271.
   PubMed Web of Science ®Google Scholar
• S. Sepehri, S. Soleymani, R. Zabihollahi, M.R. Aghasadeghi, and M. Sadat, et al. Synthesis, biological evaluation and molecular docking studies of novel 4-[4-Arylpyridin-1(4H)-yl]benzoic acid derivatives as anti-HIV-1 agents, Chem. Biodivers. 14 (12) (2017), pp. e1700295.
   Web of Science ®Google Scholar
• R.J. Smith and B.D. Aggarwala, Can the viral reservoir of latently infected CD4+ T cells be eradicated with antiretroviral HIV drugs?, J. Math. Biol. 59 (5) (2009), pp. 697–715.
   PubMed Web of Science ®Google Scholar
• B. Song, J. Lou, and Q. Wen, Modelling two different therapy strategies for drug T-20 on HIV-1 patients, Appl. Math. Mech. Engl. Ed. 32 (4) (2011), pp. 419–436.
   Google Scholar
• N.E. Tarfulea, A mathematical model for CTL effect on a latently infected cell inclusive HIV dynamics and treatment, AIP. Conf. Proc. 1895(1) (2017), pp. 070005.
   Google Scholar
• J.C. Tilton and R.W. Doms, Entry inhibitors in the treatment of HIV-1 infection, Antiviral Res. 85 (1) (2010), pp. 91–100.
   PubMed Web of Science ®Google Scholar
• N.K. Vaidya and L. Rong, Modeling pharmacodynamics on HIV latent infection: choice of drugs is key to successful cure via early therapy, SIAM J. Appl. Math. 77 (5) (2017), pp. 1781–1804.
   Web of Science ®Google Scholar
• P. van den Driessche and J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci. 180 (1-2) (2002), pp. 29–48.
   PubMed Web of Science ®Google Scholar
• X. Wang, X. Song, S. Tang, and L. Rong, Dynamics of an HIV model with multiple infection stages and treatment with different drug classes, Bull. Math. Biol. 78 (2016), pp. 323–349.
   Web of Science ®Google Scholar
• X. Wang, G. Mink, D. Lin, X. Song, and L. Rong, Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy, J. Theor. Biol. 416 (2017), pp. 16–27.
   PubMed Web of Science ®Google Scholar
• X. Wang, S. Tang, X. Song, and L. Rong, Mathematical analysis of an HIV latent infection model including both virus-to-cell infection and cell-to-cell transmission, J. Biol. Dyn. 11 (sup2) (2017), pp. 455–483.
   PubMed Web of Science ®Google Scholar
• M.J. Wawer, R.H. Gray, N.K. Sewankambo, D. Serwadda, and X. Li, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda, J. Infect Dis. 191 (9) (2005), pp. 1403–1409.
   PubMed Web of Science ®Google Scholar
• S.A. Wegner, S.K. Brodine, J.R. Mascola, S.A. Tasker, and R.A. Shaffer, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel, AIDS. 14 (8) (2000), pp. 1009–1015.
   PubMed Web of Science ®Google Scholar
• B.D. Welch, J.N. Francis, J.S. Redman, S. Paul, and M.T. Weinstock, et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance, J. Virol. 84 (21) (2010), pp. 11235–11244.
   PubMed Web of Science ®Google Scholar
• C.B. Wilen, J.C. Tilton, and R.W. Doms, HIV: cell binding and entry, Cold Spring Harb. Perspect. Med. 2(8) (2012), pp. a006866.
   PubMed Web of Science ®Google Scholar
• D. Wodarz and M.A. Nowak, Mathematical models of HIV pathogenesis and treatment, BioEssays.24 (12) (2002), pp. 1178–1187.
   PubMed Web of Science ®Google Scholar
• J.K. Wong, M. Hezareh, H.F. Günthard, D.V. Havlir, and C.C. Ignacio, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia, Sciences. 278(5341) (1997), pp. 1291–5.
   PubMed Web of Science ®Google Scholar
• H. Zhang, D. Kang, B. Huang, N. Liu, and F. Zhao, et al. Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV-1 agents: recent advances and future opportunities, Eur. J. Med. Chem. 114 (2016), pp. 65–78.
   PubMed Web of Science ®Google Scholar